Stem cell therapy in stroke

Sheng-Tzung Tsai\(^1\), Chien-Hui Lee\(^1\), Shinn-Zong Lin\(^1\), Dah-Ching Ding\(^2,3\)

\(^1\)Bioinnovation Center, Tzu Chi foundation, Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Tzu Chi University, Hualien 970, Taiwan.

\(^2\)Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Tzu Chi University, Hualien 970, Taiwan.

\(^3\)Institute of Medical Science, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.

Correspondence to: Dr. Dah-Ching Ding, MD, Ph.D., Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, No. 707, Chung-Yang Rd., Sec. 3, Hualien, 970, Taiwan, R.O.C. E-mail: dah1003@yahoo.com.tw

How to cite this article: Tsai ST, Lee CH, Lin SZ, Ding DC. Stem cell therapy in stroke. Vessel Plus 2021;5:9. http://dx.doi.org/10.20517/2574-1209.2020.73

Received: 17 Nov 2020  First Decision: 31 Dec 2020  Revised: 12 Jan 2021  Accepted: 19 Jan 2021  Published: 7 Feb 2021

Academic Editors: Elisa F. M. Ciceri, Aaron S. Dumont  Copy Editor: Yue-Yue Zhang  Production Editor: Xi-Jun Chen

Abstract

Stroke is the leading cause of neurological disability in adults worldwide and involves the significant impairment of sensory-motor function caused by cerebral ischemia and subsequent neuronal death. Owing to a lack of medical or surgical treatments to improve neurological function and neurogenesis, chronic stroke places a huge burden on patients, their families, and society. Over the past twenty years, increasing evidence from translational and clinical research has demonstrated the potential effectiveness of hematopoietic growth factors and stem cell administration or transplantation in the treatment of stroke. In particular, these studies have included granulocyte colony-stimulating factor, mesenchymal stem cells, autologous CD34\(^+\) peripheral blood stem cells, umbilical cord blood stem cells, and autologous adipose-derived mesenchymal stem cells. It is therefore important to consider the safety of these putative therapies whilst achieving the maximum benefit for patients with chronic stroke in terms of the route of administration and stem cell numbers. In this review, we discuss current evidence and the progress that has been made in our hospital, which paves the way for the next neurogenesis therapy for chronic stroke.

Keywords: Stem cells, stroke, therapy, neural stem cells, mesenchymal stem cells
INTRODUCTION

Owing to the aging global population, the socioeconomic burden of stroke is increasing, and stroke has become the second most common cause of death [1]. In Taiwan, the prevalence of stroke in those aged > 35 years has been reported as 5.95/1000 people [2]. Stroke in patients can cause long-term disability [3], and recovery is not expected within five months [4]. After this period, surviving patients are regarded as having had a chronic stroke and require long-term rehabilitation [5]. Although mobility can be partially recovered, neurological deficits resulting from neuronal loss are difficult to repair [4]; therefore, novel treatment methods are urgently required.

Patients with acute stroke are generally treated using thrombolysis intravenously with tissue plasminogen activator (tPA) within 3 h [6]; however, thrombolysis therapy can cause complications such as intracranial hemorrhage, angioedema, and major systemic hemorrhage in 6%, 5%, and 2% of patients, respectively [7]. Concomitant rehabilitation is important for stroke recovery as it can reduce disability, promote recovery, and improve quality of life [5]. Despite investigations into transcranial magnetic stimulation, there is no definitive evidence of the efficacy of this approach, while the administration of ion-channel mediators (e.g., dalfampridine) and catecholamine agonists (e.g., amphetamine) has proven to be ineffective [8].

Owing to the current shortage of effective therapies, it is important to develop novel therapeutic modalities. For instance, granulocyte colony-stimulating factor (GCSF) has been reported to modestly improve outcomes by enhancing the generation of endogenous stem cells [9]. A growing body of evidence has shown that stem cell therapy could help to reconstruct neuronal circuits after chronic stroke [10]; therefore, exogenous stem cell transplantation could underlie the next generation of therapies for patients suffering from stroke. In this review, we discuss current evidence and the progress of stem cell therapy in stroke patients that has been made in our hospital (Hualien Tzu Chi Hospital, Hualien, Taiwan).

STEM CELL THERAPY IN STROKE

Stem cell therapies for stroke aim to repair, replace, and enhance the biological function of damaged or dead cells to restore neural integrity [10]. For instance, differentiated neuronal progenitor cells may repair the functional neurons circuitry, and the paracrine factors that they secrete can promote the survival, differentiation, and migration of endogenous penumbral progenitor cells [11]. Until now, the majority of clinical trials for stroke have used cultured autologous mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord [10] administered via intravenous transplantation, which is a simple delivery technique that has been approved by government regulations [10].

PRECLINICAL MODELS

The variants of MSCs include umbilical cord blood (UCB) mononuclear cells (MNCs), human umbilical cord mesenchymal stem cells (HUCMSCs), bone marrow stem cells (BMSCs), and adipose tissue-derived stem cells (ADSCs), whereas endogenous stem cells include peripheral blood CD34 cells, GCSF-induced CD34 cells, and neural stem cells (NSCs) [12]. Each different type of stem cell has a different effect on stroke recovery; however, MSCs are currently the most widely used cell type for stroke therapy [10,11]. In this section, we introduce different types of stem cells used in preclinical research.

Umbilical cord blood mononuclear cells

Human UCB contains numerous hematopoietic and endothelial primitive cells that display strong replication capacities in vitro and in vivo. In addition, the high levels of EGF, VEGF, G-CSF, and IL-10 in UCB suggest that treatment with UCB could both restore immune homeostasis and enhance the repair of damaged neurons in patients with cerebral stroke [13]. Human UCB MNCs have been shown to exert robust therapeutic effects in experimental models of acute and subacute stroke. For example, intravenous...
UCB MNC injection was found to restore impaired exercise capabilities and exert neuroprotective effects in rodent models of cerebral stroke\(^{15-19}\). Moreover, UCB MNCs have immunomodulatory and anti-inflammatory effects in addition to their regenerative effects and can, therefore, protect penumbral tissue from further injury caused by inflammation after stroke\(^{16}\).

MNCs can also exert immunomodulatory effects by changing the phenotype of splenocytes\(^{17}\); therefore, intravenous MNC therapy may achieve neural protection by altering systemic immunomodulation in the acute or subacute stages of stroke. UCB serum was also found to contain increased heat shock protein 27 levels and exert anti-senescent effects in implanted stem cells to increase stem cell engraftment and differentiation\(^{18}\). Importantly, MNCs and other adult tissue-derived stem cells can be easily isolated and expanded in the laboratory, while the safety profile of MNCs has been consistently demonstrated in clinical trials\(^{12,14}\). A recent Phase I study was the first to demonstrate that a single intravenous administration of allogenic non-HLA matched human UCB cells is beneficial and safe for patients with acute ischemic stroke\(^{16}\). Therefore, UCB could be a source of allogeneic stem cells to treat acute cerebral infarction.

**Human umbilical cord matrix MSCs**

Human umbilical cord (HUC) is an emerging source of MSCs (HUCMSCs), which harbor rapid renewal properties and can be acquired through painless collection procedures. HUCMSCs can be derived from the cord lining, Wharton’s jelly, and perivascular tissue, and they can be easily differentiated into three germ layers that promote tissue repair. Previously, we found that HUCMSCs can improve both functional angiogenesis and neuroplasticity in animal models of stroke by upregulating \( \beta_1 \)-integrin\(^{18,19}\). In addition, HUCMSCs can be differentiated into microglial cells; they can also be induced to produce neuronal proteins and increase astrocyte protein glial fibrillary acidic protein levels\(^{20}\). Furthermore, a three-dimensional alginate scaffold has been used to effectively induce HUCMSCs to become neurons\(^{21}\). Therefore, HUCMSCs could be a source of allogeneic stem cells to treat acute cerebral infarction.

**Hematopoietic factor and endogenous stem cell mobilization**

GCSF is a growth factor that belongs to a cytokine family. GCSF can mobilize hematopoietic stem cells from bone marrow into peripheral blood. GCSF was routinely used to treat neutropenia and to reconstitute the bone marrow; however, hematopoietic stem cells in transplantation have recently been replaced by bone marrow to regenerate non-hematopoietic tissues in conditions such as myocardial infarction (MI). GCSF administration after MI has been shown to improve cardiac function and survival rates\(^{22}\), while its anti-inflammatory and anti-apoptotic effects can help prevent neuronal and glial pro-inflammatory cascades, which have both been implicated in the pathophysiology of chronic ischemic injury of the brain\(^{23}\). Activated neutrophils can produce microvascular plugging and cytotoxic substances, which will cause focal cerebral ischemic infarction. Thus, reducing inflammation in the stroke area may preserve against ischemic injury of the brain. GCSF can decrease excitotoxicity in cell culture and reduce programmed cell death in rats with cerebral ischemia\(^{24}\). Furthermore, a seminal paper confirms that GCSF reduced the infarction area and improved the recovery of rats with stroke by enhancing angiogenesis and neurogenesis\(^{23,25}\). Therefore, GCSF could be used as a therapy for acute and chronic stroke.

**MSCs and peripheral hematopoietic stem cells (CD34\(^+\))**

Owing to the efficacy of GCSF, the potential of peripheral hematopoietic stem cells (PBSCs) for treating acute and chronic cerebral ischemia was explored since the clinical use of embryonic stem cells is hindered by ethical issues. In stem cell therapy for stroke, PBSCs are regarded as a source of hematopoietic stem cells and are increasingly being employed for transplantation. GCSF can mobilize PBSCs from bone marrow and increase their numbers\(^{26}\). Indeed, intracerebral PBSC transplantation in rats with chronic cerebral ischemia has been shown to greatly improve neurological function\(^{26,27}\). The repair mechanisms involve macrophage/microglial cells derived from stem cells and the expression of \( \beta_1 \) integrin to facilitate angiogenesis in the injured brain area.
Although the intracerebral implantation of PBSCs has shown efficacy in experimental models of stroke, this strategy is highly invasive\cite{28,29}, and other studies have also improved neurological function in animal models using MSCs delivered via intravenous or intra-arterial routes\cite{30,31}. In particular, bone marrow mesenchymal stem cells reduced apoptosis and neuro-inflammation around the infarct region and enhanced angiogenesis by accumulating extensively around the infarct area and differentiating into neuronal or glial cells, as confirmed using immunohistochemical studies\cite{32}. Therefore, MSCs could be a source of autologous stem cells to treat acute and chronic cerebral infarction.

As one of the extensively used stem cells with proven safety, there is increasing need to explore the therapeutic potential of genetically-engineered MSCs with the aim to expand its application and increase its efficiency of integration into stroke lesions. The advantages of MSCs include the ability to locate themselves to the lesioned area, rapid proliferation, anti-inflammatory effects, immunomodulatory capability, strong release of paracrine or growth factors, and the potential to differentiate and integrate into various cell types and tissues. Through genetic engineering methods, MSCs could be modified by insertion of genes and their expression through viral gene transduction or a non-viral way\cite{33,34}. This could further maximize the treatment efficacy with adequate numbers of MSCs. For example, human MSCs transfected with the \textit{BDNF} gene through adenovirus enhanced functional recovery of stroke in rodents\cite{35}. Genetically-engineered MSCs were found to have about 23-fold increased expression of \textit{BDNF}, which was regarded as one of the key growth factors not only to enable neuroprotection after stroke but also to promote neuronal differentiation and repair of damaged brain.

**Neural stem cells**

Increasing evidence has also demonstrated the effect of NSCs in animal models of stroke. For instance, the implantation of intraparenchymal NSCs around the infarct region was found to improve sensorimotor dysfunction and motor disability\cite{32,36}, while further analysis of the infarct area suggested that lesion topology plays an important role in functional recovery after NSC transplantation, particularly improving outcomes for strokes confined to the striatal area. This also highlights the importance of using a novel cell-delivery method with instruments to maximize the treatment effectiveness of NSC implantation. Zhang \textit{et al}.\cite{37,38} recently showed that the intracerebral microinjection instrument could deliver unprecedented numbers of NSCs to enable better three-dimensional distribution around stroke lesions. NSC transplantation in cerebral ischemia may contribute hypoxia-inducible factor-1alpha\cite{39}, while the cell-dose dependent effect of NSCs on functional recovery suggests that a high number of stem cells is crucial to ensure adequate neurogenesis and angiogenesis\cite{40}. Above all, NSCs could be used for treating cerebral infarction.

**STEM CELL THERAPY IN CLINICAL TRIALS AT HUALIEN TZU CHI HOSPITAL**

We previously performed several clinical trials of stem cell therapy for stroke patients. In this section, we introduce GCSF, CD34$^+$, and ADSC used as the treatment of stroke in the clinical trials in our hospital.

**GCSF**

Based on its capacity to mobilize stem cells and its anti-inflammatory and neuroprotective properties, GCSF can be potentially used in a clinical setting to treat several conditions, including the treatment of MI and stroke. Experimental models of chronic stroke have revealed the synergistic benefit of using GCSF to stimulate the mobilization of hematopoietic stem cells via mechanisms involving increased cerebral blood flow, survival signal transduction, and the mobilization and differentiation of endogenous stem cells; however, the efficacy of GCSF in stroke was unclear until relatively recently.

A randomized controlled trial first demonstrated the efficacy of using GCSF to treat patients with acute ischemic stroke\cite{41}, reporting significant improvements in neurological function according to the National Institutes of Health Stroke Scale, European Stroke Scale, and Barthel Index. Several studies
have subsequently explored the benefits of GCSF in acute ischemic stroke; however, the extent of the improvements caused by GCSF may vary between patients due to hemorrhagic infarct transformation, alterations in the blood-brain barrier, overly astrogliosis, and polarized immune cell alteration after GCSF administration\[9,41,42\]. In addition, dose-dependent immunomodulation has been shown to alter the central nervous system-specific effects of GCSF after stroke; therefore, optimizing the dose or treatment time may help overcome this drawback and provide consistent efficacy during the use of GCSF\[43\]. Above all, GCSF is successfully used in the treatment of stroke patients.

**Bone marrow MSCs (CD34⁺)**

Given the preclinical evidence demonstrating the additional benefits of intracerebral PBSC implantation in animal models of chronic stroke, we initiated studies to explore the benefits of PBSCs. Among 30 chronic stroke patients, GCSF-treated group and stereotactic PBSC implantation displayed the most improvement in all functional characteristics\[28\]. Furthermore, MRI diffusion tensor imaging revealed that the implanted PBSCs ameliorated fiber tract disconnection caused by cerebral ischemia, and motor-evoked potential via transcranial magnetic stimulation was shown to establish neurophysiological re-connection. Therefore, CD34⁺ mobilized by GCSF is successfully used in the treatment of stroke patients.

**MSC and adipose-derived stem cells**

MSCs are the most common stem cells used to treat stroke, with bone marrow- and adipose tissue-derived stem cells being the most explored cell sources\[44\], since autologous stem cells can be used to treat acute or chronic stroke without carcinogenicity, immune rejection, or ethical concerns\[45\]. In particular, ADSCs can be obtained from subcutaneous adipose tissue fragments or liposuction aspirates easily. ADSCs can be expanded in vitro, and there are no ethical concerns regarding various clinical applications. The autologous ADSCs administration into the injured penumbra for chronic stroke patients was shown to result in functional regeneration\[46,47\]; therefore, we undertook the first Phase I clinical study using the stereotactic implantation of autologous ADSCs to treat patients with chronic stroke at Hualien Tzu Chi Hospital in Taiwan. Our preliminary results indicate good safety and significantly improved sensorimotor function in the study participants. Above all, ADSC could be safely and effectively used in the treatment for stroke patients.

**ADMINISTRATIVE PATHWAY AND TRANSPLANTED CELL NUMBERS**

Previous clinical studies have utilized several different cell-transplantation techniques. For instance, in the MultiStem study, patients were administered 1200 million cells via intravenous (IV) injection\[48\]. Although IV route is considered noninvasive and facilitates drug administration, some preclinical studies have suggested that most of the stem cells in circulation will be trapped in the lungs and liver, thus stem cells were not able to cross the blood-brain barrier\[49\]. Moreover, chemotactic signaling from the injured brain areas is not active during chronic strokes\[50\]. The primary mechanism of intravenous circulated stem cells may be contributed by reducing immune response in the stroke subacute phase. A Phase II trial of subacute stroke has reported that intravenous administration of bone marrow-derived mononuclear cells is safe but does not affect measures of neurological function\[51\].

Stem cells can be administered by intra-arterial route to transfer into the brain directly; however, there is concern that this method could result in possible cell clumping, leading to microthrombi and potential damage\[52\]. Sung et al.\[53\] conducted a Phase I clinical trial in which circulation-derived autologous CD34⁺ cells (3.0 × 10⁷ cells/patient) were isolated and administered via intra-carotid artery transfusion to elderly patients with chronic ischemic stroke. To avoid microembolization, the CD34⁺ cells were first filtered with an embolic protection filter, slowly transfused into the ipsilateral internal carotid artery, and finally into the infarct area\[53\]. Although the neurological recovery achieved by intracerebroventricular (ICV) ADSC administration was found to be superior to that achieved via the IV route\[54\], the invasive procedure to
deliver stem cells may cause surgical complications or intracerebral trauma. Thus, ICV-transplanted stem cells could be used to attract IV administered stem cells by its concentration slope of homing factors. Therefore, the route of administration and stem cell numbers are important factors for stem cell therapy in stroke patients.

**PERSPECTIVES**

Although stroke is currently treated using tPA and rehabilitation, new therapies are constantly being developed, among which stem cell therapies are the most promising. The variants of MSCs include UCBMNCs, HUCMSCs, BMSCs, and ADSCs, whereas endogenous stem cells include peripheral blood CD34 cells, GCSF-induced CD34 cells, and NSCs. Each different type of stem cell has a different effect on stroke recovery; however, MSCs are currently the most widely used cell type for stroke therapy.

Stem cell therapies have several advantages, including self-renewal, differentiation, and immunomodulatory capabilities. MSCs display self-renewal capabilities. A previous study tested this phenomenon and reported that single cell-derived clones display different self-renewal potentials and, thus, may harbor different differentiation capacities. In particular, MSCs can differentiate into adipocytes, osteocytes, chondrocytes, and neuron-like cells, depending on the factors that they are exposed to, suggesting that MSCs could be used to treat stroke.

IV and stereotactic stem cell transplantation are commonly used routes of administration when treating stroke; however, IV is used most often. In our hospital, we used stereotactic transplantation based on the site of injection; however, this method may require specific training. There is currently no consensus regarding the number of transplanted stem cells, since too many cells can cause volume-compression effects and too few cells can be ineffective. While previous trials have used $1 \times 10^7$ to $12 \times 10^8$ cells, we transplanted $1 \times 10^8$ cells in our clinical trial and demonstrated good preliminary safety; however, the dosage may vary due to stroke volume and site. The landscape of this review is summarized in **Figure 1**.
CONCLUSIONS

Stroke is the leading global cause of adult neurological disability, which causes sensory-motor function impairment and neuronal death; however, there are currently no medical or surgical treatments to improve neurological function and neurogenesis in chronic stroke. Growing translational and clinical evidence has demonstrated the potential effectiveness of hematopoietic growth factors and stem cell transplantation as therapies for stroke, including GCSF, mesenchymal stem cells, autologous CD34+ peripheral blood stem cells, umbilical cord blood and stromal stem cells, and autologous adipose-derived mesenchymal stem cells. This review not only highlights the safety aspects but also indicates how to achieve the maximum benefit for patients with chronic stroke by considering the route of administration and stem cell numbers. Therefore, these studies pave the way for the next generation of neurogenesis therapies for chronic stroke.

DECLARATIONS

Authors’ contributions

Literature review: Tsai ST, Ding DC
Writing the manuscript: Tsai ST, Lee CH, Lin SZ, Ding DC
Organizing the manuscript: Ding DC
Discussion of the manuscript: Tsai ST, Lee CH, Ding DC, Lin SZ

Availability of data and materials

Not applicable.

Financial support and sponsorship

The work was supported by the Buddhist Tzu Chi Medical Foundation (TCMF-EP-108-02 to DCD, TCMF-CWP-109-01, TCMF-MP 108-01-03, Buddhist Tzu Chi Medical Foundation).

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2021.

REFERENCES


